USANA plans China inroads
This article was originally published in The Tan Sheet
Executive Summary
USANA Health Sciences begins offering its nutritional and personal-care products in China - a "significant growth opportunity," the firm announced May 24 at its Asia Pacific convention in Hong Kong. Asia Pacific countries already drive the bulk of the Salt Lake City-based direct-seller's sales growth; net sales in the region increased 41.5 percent to $58.6 million in USANA's first quarter (1"The Tan Sheet" May 3, 2010). The firm said May 21 it will introduce to Asia Pacific USANA Calming Tea with L-theanine and Sense Blanc Balance Serum and Moisture Masq
You may also be interested in...
Sales & Earnings In Brief
Sanofi seeks more acquisitions: Sanofi-Aventis continues to "hunt" for bolt-on acquisitions to further diversify its portfolio and feed its pipeline now that it has "properly bedded down and integrated" Chattem, said CEO Chris Viehbacher. He told analysts April 29 that the environment is "quite promising" for acquisitions and Sanofi is "aggressively pursuing external growth opportunities." The Chattem deal significantly boosted Sanofi's consumer health care business, which grew 42.5 percent to €499 million ($661.1 million) in the firm's fiscal 2010 first quarter, according to a same-day release (1"The Tan Sheet" March 15, 2010). Viehbacher lauded Chattem as a keystone in the company's future as a switch platform for the allergy medication Allegra. He noted Sanofi filed the paperwork with FDA for the switch in March; he expects the switch evaluation to take the same amount of time as other new product applications. Prescription sales for Allegra fell 27.1 percent in the quarter due to new competition from generics launched in the U.S. last November. Overall sales for the Paris-based firm grew 5.8 percent, according to the release
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.